Age-related macular degeneration (AMD) affects more than 5 million people worldwide, and until now no treatment could restore vision for those with the condition. The Prima system, an implant that includes a retinal component, is the first to change that, according to MIT Technology Review.
The system received approval in Europe in July and is now awaiting clearance from the US Food and Drug Administration. This marks a significant step for a condition that previously had no restorative options.
The report highlights that the Prima system is designed to restore sight for patients with AMD, offering hope to millions. While the technology is not yet available in the US, its European approval suggests a path forward.